PDT Partners’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$748K Buy
125,587
+38,718
+45% +$184K 0.04% 366
2026
Q2
$385K Hold
86,869
– – 0.02% 425
2026
Q1
$380K Sell
86,869
-5,000
-5% -$23.6K 0.02% 443
2025
Q4
$464K Hold
91,869
– – 0.03% 433
2025
Q3
$319K Hold
91,869
– – 0.02% 505
2025
Q2
$312K Sell
91,869
-42,196
-31% -$141K 0.02% 590
2025
Q1
$538K Buy
+134,065
New +$695K 0.04% 517
2023
Q3
– Sell
-115,545
Closed -$987K – 605
2023
Q2
$987K Buy
115,545
+34,254
+42% +$307K 0.14% 253
2023
Q1
$747K Buy
81,291
+49,910
+159% +$537K 0.1% 323
2022
Q4
$320K Sell
31,381
-55
-0.2% -$739 0.05% 472
2022
Q3
$463K Sell
31,436
-14,732
-32% -$191K 0.07% 455
2022
Q2
$495K Buy
46,168
+26,733
+138% +$266K 0.04% 605
2022
Q1
$210K Buy
+19,435
New +$262K 0.02% 807

Other funds holding CTKB

PDT Partners's CTKB Position: Q3 2026 in Review

PDT Partners increased its Cytek Biosciences (CTKB) stake by 45% in Q3 2026, buying an estimated $184K and bringing the position to 125,587 shares worth $748K. The position accounts for 0.04% of the portfolio, ranked #366.

PDT Partners first reported a position in CTKB in Q1 2022 and has held it in 13 quarters since. The position peaked at $987K in Q2 2023. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • PDT Partners held 125,587 shares of Cytek Biosciences worth $748K as of Q3 2026.
  • PDT Partners bought 38,718 Cytek Biosciences shares in Q3 2026, an estimated $184K.
  • Cytek Biosciences made up 0.04% of PDT Partners's portfolio in Q3 2026, its #366 holding.
  • PDT Partners first reported a position in Cytek Biosciences in Q1 2022 and has held it in 13 quarters since.
  • PDT Partners's Cytek Biosciences position peaked at $987K in Q2 2023.
  • 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on PDT Partners's 13F filing for Q3 2026, filed 16 Nov 2026.